

Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II)

Mathilde Boussac, Christophe Arbus, Helene Klinger, Alexandre Eusebio, Elodie Hainque, Jean Christophe Corvol, Olivier Rascol, Vanessa Rousseau,

Estelle Harroch, Charlotte Scotto D'apollonia, et al.

▶ To cite this version:

Mathilde Boussac, Christophe Arbus, Helene Klinger, Alexandre Eusebio, Elodie Hainque, et al.. Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II). Journal of Parkinson's disease, 2022, 12 (2), pp.699-711. 10.3233/JPD-212883 . hal-03513907

HAL Id: hal-03513907 https://hal.science/hal-03513907

Submitted on 17 Jun2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II)

⁵ Mathilde Boussac^{a,*}, Christophe Arbus^b, Helene Klinger^c, Alexandre Eusebio^d, Elodie Hainque^e,

- ⁶ Jean Christophe Corvol^f, Olivier Rascol^{a,g}, Vanessa Rousseau^g, Estelle Harroch^g,
- ⁷ Charlotte Scotto d'Apollonia^g, Aurélie Croiset^h, Fabienne Ory-Magne^{a,g}, Amaury De Barros^{a,i},
- ⁸ Margherita Fabbri^{a,g}, Caroline Moreau^j, Anne-Sophie Rolland^j, Isabelle Benatru^k, Mathieu Anheim¹,
- Ana-Raquel Marques^m, David Maltêteⁿ, Sophie Drapier^o, Béchir Jarraya^p, Cécile Hubsch^q,
- ¹⁰ Dominique Guehl^{r,s}, Mylène Meyer^t, Tiphaine Rouaud^u, Bruno Giordana^v, Mélissa Tir^w,
- ¹¹ David Devos^j and Christine Brefel-Courbon^{a,g} for the PREDISTIM study group
- ¹² ^aToulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France
- ¹³ ^bPsychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France
- ¹⁴ ^cHospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Lyon, France
- ¹⁵ ^dAix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement,
- 16 and UMR CNRS, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France
- ¹⁷ ^eDépartement de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France et Faculté de Médecine de
- 18 Sorbonne Université, Paris, France
- ^fSorbonne Université, Paris Brain Institute ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris,
 Pitié-Salpêtrière Hospital, NS-PARK/FCRIN, Department of Neurology, Paris, France
- ²¹ ^gDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation
- 22 Center, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration),
- 23 Toulouse, NS-PARK/FCRIN Network, France
- ^hCERPPS—Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II
 Jean-Jaurès, Toulouse, France
- ¹Department of Neurosurgery, Toulouse University Hospital, Toulouse, France
- ²⁷ ^jDepartment of Medical Pharmacology, Neurology and Movement Disorders Department, Referent center of
- Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, Lille,
- 29 NS-PARK/FCRIN Network, France
- ⁸ ^kNeurology Department, University Hospital of Poitiers, Poitiers, France; INSERM, CHU de Poitiers, University
- of Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France
- ³² ¹Service de Neurologie, Hôpitaux Universitaires de Strasbourg; Institut de Génétique et de Biologie Moléculaire
- et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch; Fédération de
- ³⁴ Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France ^mUniversité Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand University Hospital, Neurology department, France

31024 Toulouse, France. Tel.: +33 05 62 74 61 99; E-mail: math ilde.boussac@inserm.fr.

^{*}Correspondence to: Mathilde Boussac, PhD Student, Unité ToNIC, Toulouse NeuroImaging Center, UMR 1214 – INSERM/ UPS – CHU PURPAN – Pavillon Baudot, Place du Dr Baylac,

ⁿDepartment of Neurology, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France ^oCHU Rennes, Service de neurologie, CIC-INSERM 1414, Rennes, France

^pPôle Neurosciences, Foch Hospital, Suresnes; Université Paris-Saclay, UVSQ, INSERM U992,

CEA Paris-Saclay, Neurospin, France

^qHôpital Fondation A de Rothschild, Service de Recherche Clinique, Paris, France

^rInstitut des Maladies Neurodégénératives (IMN, CNRS U5393), Université de Bordeaux, Bordeaux, France ^sService de Neurophysiologie Clinique, Pôle des Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France ^tService de Neurologie, Hôpital Central, CHRU de Nancy, Nancy Cedex, France

^uClinique Neurologique, Hôpital Guillaume et René Laennec, Boulevard Jacques Monod, Nantes Cedex, France ^vCHU Nice, Department of Psychiatry and Psychotherapy, Nice, France

^wDepartment of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France

Accepted 17 November 2021

Abstract.

Background: Deep brain stimulation of the sub-thalamic nucleus (DBS-STN) reduces symptoms in Parkinson's disease (PD) patients with motor fluctuations. However, some patients may not feel ameliorated afterwards, despite an objective motor improvement. It is thus important to find new predictors of patients' quality of life (QoL) amelioration after DBS-STN. We hypothesized that personality dimensions might affect QoL after DBS-STN.

Objective: To evaluate associations between personality dimensions and QoL improvement one year after DBS-STN.

Methods: DBS-STN-PD patients (n = 303) having answered the "Temperament and Character Inventory" (TCI) before surgery and the PDQ-39 before and one year after surgery were included, from the cohort study PREDI-STIM. Linear regression models were used to evaluate associations between TCI dimensions and change in PDQ-39 scores after DBS-STN. **Results:** Novelty Seeking and Cooperativeness scores before surgery were positively associated with PDQ-39 scores improvement after DBS-STN (FDR-adjusted p < 0.01). Moreover, paradoxically unimproved patients with deterioration of their PDQ-39 scores after DBS-STN despite improvement of their MDS-UPDRS-IV scores had lower Cooperativeness scores, while paradoxically improved patients with amelioration of their PDQ-39 scores despite deterioration of their MDS-UPDRS-IV scores had higher Reward Dependence scores.

Conclusion: Some presurgical personality dimensions were significantly associated with QoL amelioration and discrepancy between motor state and QoL changes after DBS-STN in PD. Educational programs before DBS-STN should take in account patient personality dimensions to better deal with their expectations.

Keywords: Cooperativeness, DBS-STN, novelty seeking, Parkinson's disease, quality of life

37 INTRODUCTION

Deep brain stimulation of the sub-thalamic nucleus 38 (DBS-STN) is proposed to Parkinson's disease (PD) 39 patients with motor fluctuations and generally leads 40 to a great improvement of their quality of life (QoL) 41 [1-4]. Nonetheless, some patients do not feel DBS 42 benefits despite objective motor improvement [5, 6]. 43 That is why it seems crucial to find some individual 44 predictive factors of QoL improvement after DBS-45 STN in order to assure at best patients' amelioration 46 after this invasive therapy. 47

48 QoL improvement is an important outcome when
 49 evaluating treatment efficiency. It depends on both

objective and subjective factors such as physical and psychological health, as well as personal feeling of well-being and happiness experienced [7, 8].

Because personality is a very individual characteristic and describes how people think, behave and manage their life [9], it seems a factor of interest to predict QoL. To assess personality, several questionnaires have been developed, based on different concepts. From them, the Temperament and Character Inventory (TCI) evaluates personality through seven dimensions [10]. It is derived from the neurobiological and psychological concept of personality made by Cloninger [9]. The TCI was already used in several studies assessing PD personality [11] and was

62

63

50

51

validated by its stability [9, 12–15]. Moreover, our preceding study on PD patients with motor fluctuations has shown the adequacy of the TCI personality questionnaire on predicting QoL in this population before DBS-STN [16].

M. Boussac et al. / Personality and QoL Evolution after DBS in PD

before DBS-STN [16].
Our first objective was thus to identify associations between presurgical personality dimensions and
QoL improvement one year after DBS-STN. Our
second objective was to seek for characteristics of
PD patients experiencing discrepancy between motor
complications and QoL changes after DBS.

75 MATERIALS AND METHODS

This study is an ancillary analysis using data col-76 lected from the PREDISTIM cohort which principal 77 objective is to define the predictive factors of the ther-78 apeutic response to DBS-STN on the long-term QoL 79 in PD. PREDISTIM is an ongoing prospective multi-80 centric cohort (Protocol 2013-A00193-42) sponsored 81 by the University Hospital of Lille, conducted in 17 82 PD expert centers from the clinical research network 83 in France (NS-Park/F-Crin), approved from the CPP 84 Nord Ouest-IV Ethical Committee and registered in 85 the ClinicalTrials.gov website (NCT02360683). 86

87 Patients

64

65

66

67

Briefly, patients undergoing DBS-STN in one of 88 the participating centers were consecutive included 89 into the study between 11/2013 and 09/2019. Inclu-90 sion criteria are a diagnosis of PD according to the 91 UKPDSBB, disease duration > 5 years, age between 92 18 and 75 and indication of DBS-STN. Exclusion 93 criteria are atypical parkinsonism, severe cogni-94 tive impairment (Montreal Cognitive Assessment 95 (MoCA) score < 23), severe psychiatric disorders 96 (following psychiatric evaluation by a psychiatrist), 97 levodopa motor response < 30% and contra-indica-98 tions to surgery. 99

Patients gave written informed consent, the study was conducted according to the good clinical practice, local regulations and data collection was compliant with GDPR rules.

104 Study design and clinical measures

For PREDISTIM, clinical data was collected at baseline, and then at 1-, 3-, and 5-years post-surgery. Clinical assessments at each visit included collection of demographic data, medical and treatment history, MDS-UPDRS part I-IV [17], part-III being performed in OFF and ON state during a standardized acute levodopa challenge, neuropsychological testing, patient and caregivers' questionnaires. Along our ancillary study, only one personality questionnaire was added to evaluation at baseline: the TCI. Here, only patients evaluated before (V0) and after one year of DBS-STN (V1) were used in this study.

The MDS-UPDRS-III was evaluated for two conditions at V0: OFF and ON medication; and for four conditions at V1: ON stimulation ON medication (stimON-medON), ON stimulation OFF medication (stimOFF-medOFF), OFF stimulation ON medication (stimOFF-medON) and OFF stimulation OFF medication (stimOFF-medOFF).

The total Levodopa Equivalent Dose (LED) was calculated [18].

The Parkinson's Disease Questionnaire 39-items (PDQ-39) is a self-questionnaire evaluating specifically QoL of PD patients [19] and was assessed at V0 and V1. Its eight sub-scales can be divided into a Physical Component Score ("Mobility", "Activities of Daily Living" and "Bodily Discomfort" subscores) and a Mental Component Score ("Emotional Well-Being", "Stigma", "Social Support", "Cognition" and "Communication" sub-scores) of QoL.

134 The TCI was measured only at V0 in order to 135 serve as predictive factor of QoL improvement after 136 DBS-STN. It is a self-questionnaire of 226 binary 137 questions used to assess patients' personality through 138 seven dimensions [10]. It includes four temperaments 139 (which are supposed to be genetically determined 140 personality traits [9]): Novelty Seeking (NS), Harm 141 Avoidance (HA), Reward Dependence (RD), and 142 Persistence (P); and three characters (which are 143 developmental personality traits evolving through 144 time and life history [9]): Self-Directedness (SD), 145 Cooperativeness (C), and Self-Transcendence (ST). 146 Each of these seven personality dimensions are mea-147 sured by an independent score: higher is the score, 148 higher the individual will present the personality 149 characteristic associated. NS corresponds to impul-150 sive and curious temperament; HA to anxious and 151 pessimist traits; RD to socially attached and sensi-152 tive individuals; P to hardworking and perseverant 153 personality; and the three characters are associated 154 to levels of maturity: SD to individual maturity, C to 155 social maturity, and ST to spiritual maturity. Except 156 the P, each of these seven dimensions is subdivided 157 into sub-dimensions: NS and HA are formed by 4 158 sub-dimensions, RD and ST by 3, and SD and C by 5. 159 Each of these twenty-four sub-dimensions represents 160

113 114 115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

100

110

111

- a specific aspect of the global dimension, also rangingin a spectrum of scores.
- 163 Statistical analyses

Descriptive analyses were performed. Moreover,
Kruskal-Wallis tests or ANOVA (according to normality of our data) followed by *post-hoc* analysis
were done to control for homogeneity across centers
for several variables (age, disease duration, LED at
V0, percentage of PDQ-39 total score and sub-scores
changes at V1, and TCI dimensions).

171 Impact of DBS-STN at V1

After DBS-STN, changes between V0 and V1 in LED, MDS-UPDRS, PDQ-39, Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA), Lille Apathy Rating Scale (LARS), and MoCA were checked (Wilcoxon Signed Rank Test for Paired Samples).

Associations between TCI dimensions and PDQ-39 scores at V0

Linear regression models were performed to test 180 the association between the different PDO-39 sub-181 scores and total score at V0 and the seven TCI 182 dimensions. Models were univariate with only one 183 explanatory variable (each TCI dimensions) by mod-184 els, resulting in seven models per response variable 185 (each PDO-39 scores) which were adjusted by age, 186 sex, disease duration and LED at V0. A False Dis-187 covery Rate (FDR) correction was applied for 31 188 comparisons with calculation of q values (corre-189 sponding to FDR adjusted p values). We have chosen 190 univariate models to study if some TCI personal-191 ity dimensions were separately associated with QoL. 192 Moreover, because studying TCI sub-dimensions as 193 well as main dimensions seemed of interest, multi-194 variate analysis seemed inappropriate since too many 195 explanatory variables would be used (that is 31 vari-196 ables - 7 dimensions plus 24 sub-dimensions) which 197 can be too much in view of the parsimony rule. 198

Associations between MDS-UPDRS and PDQ-39 scores at V1

These associations were tested using linear regression models adjusted by age, sex, disease duration, and LED at V1. The PDQ-39 scores at V1 served as response variables (the total and eight PDQ-39 sub-scores) and the MDS-UPDRS (part-I, part-II stimON-medON, part-III stimON-medON and part-IV) scores at V1 as explanatory variables. Models were univariate with only one explanatory variable by models, resulting in four models per response variable. An FDR correction was applied for 4 comparisons.

Associations between TCI dimensions at V0 and PDQ-39 changes at V1

Percentages of changes from V0 to V1 were calculated from the PDQ-39 total and sub-scores. Linear regression models were performed. The response variables corresponded to each calculated percentages of PDQ-39 change. The explanatory variables corresponded to each TCI dimensions and sub-dimensions. As explained above, models were univariate with only one explanatory variable by models, resulting in thirty-one models per response variable, adjusted by age, sex, disease duration and LED at V0, to account for any potential center effect. The same FDR correction was applied with q values calculation for 31 comparisons.

PD population was also divided into two groups according to the Minimal Clinically Important Difference (MCID) of PDQ-39 total score change [20]: an "improvement" (difference of PDQ-39 total score between V1 and V0 < -4.72) and a "no improvement" group (difference of PDQ-39 total score between V1 and V0 ≥ -4.72). TCI dimensions and subdimensions scores were compared in these groups (two-sample Mann-Whitney tests with FDR correction for 31 comparisons).

Differences between groups of responding patients

As supplementary exploratory analysis, we have chosen to study discrepancy between motor complications (MDS-UPDRS-IV) and QoL (PDQ-39 total) evolution. From the two PDQ-39 groups above and two similar MDS-UPDRS-IV groups (an "improvement" group based on MCID [21] (difference of MDS-UPDRS-IV score between V1 and V0 <-0.9) and a "no improvement" group (difference of MDS-UPDRS-IV score between V1 and V0 \geq -0.9)), PD patients were divided into three final groups of responding patients: a "paradoxically unimproved" group (MDS-UPDRS "improvement" group and PDQ-39 "no improvement" group), a "realistic" group (MDS-UPDRS and PDQ-39 "improvement" groups or MDS-UPDRS and PDQ-39 "no improvement" groups) and a "paradoxically improved" group (MDS-UPDRS "no improvement" group and PDQ-39 "improvement" group). Each group were compared two by two in terms of TCI dimensions and

252

253

254

255

256

257

208

209

210

	$V0$ (mean \pm SD)	$V1$ (mean \pm SD)	р	CI of the difference
4.22	60.0 ± 7.4	(incar ± 5D)	1	
Age Disease duration	10.1 ± 3.9	1	1	1
Novelty Seeking	10.1 ± 3.9 16.7 ± 5.0	1	1	1
Harm Avoidance	10.7 ± 3.0 17.4 ± 6.5	1	1	1
Reward Dependence	17.4 ± 0.3 15.4 ± 3.5	1	1	1
Persistence	13.4 ± 3.3 5.4 ± 1.7	1	1	1
Self-Directedness	34.4 ± 6.0	1	1	1
Cooperativeness	34.4 ± 0.0 33.8 ± 4.7	1	1	1
Self-Transcendence	12.3 ± 5.8	1	/	1
LED	12.5 ± 3.8 1348.6 ± 740.2	689.6 ± 480.3	$9 \times 10^{-33 **}$	535.7; 674.0
HAMD	5.2 ± 4.1	4.6 ± 4.1	$4 \times 10^{-02*}$	0.0; 1.5
HAMA	5.2 ± 4.1 5.9 ± 5.1	4.0 ± 4.1 4.7 ± 4.2	$2 \times 10^{-03**}$	0.5; 2.0
LARS	-27.9 ± 5.7	-25.2 ± 8.3	$1 \times 10^{-06**}$	-3.0; -1.0
MoCA	-27.9 ± 3.7 27.1 ± 2.2	-23.2 ± 8.3 25.9 ± 2.8	$1 \times 10^{-11**}$ $1 \times 10^{-11**}$	-3.0; -1.0
MDS-UPDRS I	27.1 ± 2.2 10.9 ± 5	23.9 ± 2.8 9.3 ± 5.2	$5 \times 10^{-06**}$,
MDS-UPDRS II OFF [†]			$3 \times 10^{-12**}$ $9 \times 10^{-12**}$	1.0; 2.5
	18.7 ± 7.6	15.1 ± 8.5	$9 \times 10^{-05**}$	3.5; 5.5
MDS-UPDRS II ON [‡]	6.5 ± 5.9	8.1 ± 5.8	$8 \times 10^{-05**}$	-2.5; -1.0
MDS-UPDRS III OFF [†]	43 ± 16.2	21.8 ± 12.9	$3 \times 10^{-46 **}$	19.0; 22.5
MDS-UPDRS III ON [‡]	12.5 ± 7.8	10.8 ± 7.9	$3 \times 10^{-02*}$	0.0; 2.5
MDS-UPDRS IV	8.8 ± 3.3	4.1 ± 3.7	$3 \times 10^{-33**}$	4.5; 5.5
PDQ-39 Total	31.3 ± 11.4	26.8 ± 13.5	$3 \times 10^{-11**}$	3.4; 6.0
PDQ-39 Mobility	36.7 ± 20.4	32.6 ± 22.7	$2 \times 10^{-03**}$	1.3; 6.3
PDQ-39 ADL	37.7 ± 18.1	29.2 ± 20	$5 \times 10^{-13 * *}$	8.3; 12.5
PDQ-39 Emotional Well-being	32 ± 17.7	31.1 ± 19.2	0.30	-0.00004; 4.2
PDQ-39 Stigma	33.2 ± 22.3	23.1 ± 20.3	$5\times 10^{-15**}$	9.4; 15.6
PDQ-39 Social support	11.7 ± 15.9	14 ± 18	$1 \times 10^{-02*}$	-8.3; 0.0
PDQ-39 Cognition	28.3 ± 17.1	24 ± 17.2	$6 \times 10^{-05**}$	3.1; 6.3
PDQ-39 Communication	24.9 ± 17.9	28.1 ± 21	$3 \times 10^{-03**}$	-8.3; 0.0
PDQ-39 Bodily discomfort	46.3 ± 21.1	32.5 ± 21.4	$9 \times 10^{-19**}$	12.5; 20.8

Table 1 Description of TCI dimensions and clinical characteristics at V0 and V1

Mann-Whitney tests: *p < 0.05; ** $p \le 0.01$; CI, confidence interval of the difference in means at 95% confidence level; V0, baseline; V1, one year after DBS-STN; [†]MDS-UPDRS medOFF (V0) vs. stimON-medOFF (V1); [‡]MDS-UPDRS medON (V0) vs. stimON-medON (V1); ADL, Activities of Daily Living.

ACCEPTED MANUSCRIPT - CLEAN COPY

cognitive and behavioral (HAMD, HAMA, LARS,
and MoCA) changes after DBS-STN (two-sample
Mann-Whitney tests). FDR adjusted *p* values (q values) were calculated for 7 comparisons for the TCI
dimensions analysis and for 4 comparisons for the
cognitive and behavioral changes analysis.

All analyses were conducted on R Studio Software Version 1.1.456 and a threshold of bilateral statistical significance of 0.05 was used. As explained above, FDR corrections were applied and interpretations were made carefully according to strength of the results.

270 RESULTS

Three hundred and three PD patients were enrolled in this study (204 men (67.3%) and 99 women (32.7%)) (Table 1). Statistical testing did not show relevant significant differences across centers: only age and disease duration shown significant differences between centers in the Kruskal-Wallis testing (p = 0.003 and p = 0.03, respectively) which no more reached significance during the *post-hoc* analysis; LED at V0, percentage of PDQ-39 changes at V1 and TCI dimensions were not different between centers (p > 0.05). In any case, age, disease duration, sex and LED were used as adjustment variables in the linear regression models to control for any potential center effect.

Impact of DBS-STN at V1 (Table 1)

One year after DBS-STN, PD patients had a significant decrease in their dopaminergic treatments (LED). HAMD, HAMA, and MoCA scores significantly decreased after DBS, while LARS scores slightly increased.

All parts of the MDS-UPDRS scores improved significantly after DBS-STN except the part-II-ON which worsened.

285

286

287

288

289

290

291

292

293

276

295

296

297

298

299

300

301

Percentage of PDQ-39 evolution	TCI dimensions	coefficients	Р	q	R2	CI
% PDQ-39 Total	NS	-1.02	0.04*	0.46	0.07	-2.01; -0.03
	HA4	-2.41	0.03*	0.46	0.07	-4.62; -0.21
	C3	-4.48	0.03*	0.46	0.07	-8.47; -0.49
% PDQ-39 Mobility	NS1	-9.42	0.0006**	0.02 *	0.05	-14.75; -4.08
	NS4	-7.34	0.047*	0.29	0.02	-14.55; -0.13
	С	-3.11	0.01**	0.12	0.03	-5.60; -0.62
	C1	-13.17	0.004**	0.04 *	0.04	-22.15; -4.19
	C4	-9.30	0.004**	0.04 *	0.04	-15.65; -2.96
% PDQ-39 ADL	C3	-10.24	0.047*	0.978	0.02	-20.30; -0.18
% PDQ-39 Emotional Well-Being	HA	-2.30	0.02*	0.37	0.04	-4.29; -0.32
-	HA4	-7.54	0.01**	0.35	0.05	-13.34; -1.74
	Р	8.18	0.04*	0.40	0.04	0.46; 14.89
% PDQ-39 Stigma	RD	-2.39	0.03*	0.40	0.01	-4.53; -0.24
	RD3	-5.84	0.04*	0.40	0.01	-11.41; -0.28
	ST3	4.20	0.03*	0.40	0.01	0.40; 8.01
% PDQ-39 Social Support	ST	1.80	0.02*	0.31	0.02	0.29; 3.31
	ST3	5.30	0.02*	0.31	0.02	0.92; 9.68
% PDQ-39 Cognition	NS	-2.56	0.009**	0.262	0.03	-4.45; -0.66
	SD	1.63	0.04*	0.26	0.02	0.07; 3.19
	SD1	6.84	0.02^{*}	0.26	0.02	0.98; 12.70
	C1	7.72	0.04*	0.26	0.02	0.30; 15.13
	C2	6.56	0.04*	0.26	0.02	0.27; 12.85
% PDQ-39 Communication	HA4	-5.55	0.04*	0.70	0.00	-10.95; -0.15
% PDQ-39 Bodily Discomfort	NS	-1.90	0.01**	0.34	0.02	-3.37; -0.43
	NS1	-3.78	0.03*	0.34	0.02	-7.20; -0.35
	C3	-6.50	0.03*	0.34	0.02	-12.45; -0.56

 Table 2

 Significant associations between TCI dimensions at V0 and percentages of PDQ-39 change at V1 (n = 303)

Adjusted linear regression models: *p < 0.05; $**p \le 0.01$; q, FDR adjusted q value; significant *p* value in bold; CI, confidence interval at 95% confidence level; NS, Novelty Seeking; HA4, Fatigability; C3, Helpfulness; NS1, Exploratory excitability; NS4, Disorderliness; C, Cooperativeness; C1, Social acceptance; C4, Compassion; HA, Harm Avoidance; P, Persistence; RD, Reward Dependence; RD3, Dependence; ST3, Spiritual acceptance; ST, Self-Transcendence; SD, Self-Directedness; SD1, Responsibility; C2, Empathy.

Total PDQ-39 scores significantly improved after one year of DBS-STN as well as the "Mobility", "Activities of Daily Living", "Stigma", "Cognition", and "Bodily Discomfort" sub-scores, whereas the "Emotional Well-Being" sub-score did not significantly change. The "Social Support" and "Communication" sub-scores significantly worsened after surgery.

Associations between TCI dimensions and PDQ-39 scores at V0

TCI dimensions were mainly associated with 304 the Mental Component Score of the PDO-39 at 305 V0. Indeed, the linear regression models between 306 TCI dimensions and PDQ-39 sub-scores at V0 307 showed that HA and ST scores were significantly 308 and positively associated with PDQ-39 total score 309 $(q = 1 \times 10^{-8}, \mathbb{R}^2 = 0.16; \text{ and } q = 9 \times 10^{-3}, \mathbb{R}^2 = 0.07,$ 310 respectively) whereas SD scores were significantly 311 and negatively associated with PDQ-39 total score 312 $(q = 2 \times 10^{-7}, R^2 = 0.14)).$

Associations between MDS-UPDRS and PDQ-39 scores at V1

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

At V1, the MDS-UPDRS part-I and part-II stimON-medON were positively associated with PDQ-39 total and 8 sub-scores (q < 0.01). The MDS-UPDRS part-III stimON-medON and part-IV were positively associated with PDQ-39 total score ($q < 10^{-4}$), most of the Physical Component Score ("Mobility" and "Activities of Daily Living") ($p < 10^{-3}$) and part of the Mental Component Score ("Emotional Well-Being", "Stigma", and "Communication") (q < 0.05). The "Bodily Discomfort" was associated only with the MDS-UPDRS part-IV ($q < 10^{-3}$).

Associations between TCI dimensions at V0 and PDQ-39 changes at V1 (n = 303)

There were significant associations between TCI dimensions and PDQ-39 sub-scores change at V1 (Table 2). We mainly considered TCI dimensions

Differences of TCI dimensions scores between PDQ-39 total improvement groups at V1 ($n = 303$)							
				Mean ± SD			
TCI dimensions	р	q	CI	PDQ-39 total "improvement" group (<i>n</i> = 150)	PDQ-39 total "no improvement" group $(n = 153)$		
HA4	0.03*	0.29	0; 1.0	5.4 ± 2.0	4.7 ± 2.4		
С	0.01*	0.47	0; 2.0	34.4 ± 4.5	33.2 ± 4.7		
C3	0.006**	0.78	0, 0.9	6.6 ± 1.2	6.2 ± 1.3		

Table 3

Mann-Whitney tests: p < 0.05; p < 0.01; q, FDR adjusted p value; CI, confidence interval of the difference at 95% confidence level; HA4, Fatigability; C, Cooperativeness; C3, Helpfulness.

ACCEPTED MANUSCRIPT - CLEAN COPY




Fig. 1. Differences in Reward Dependence scores between groups of responding patients.

having the strongest association with PDQ-39 subscores (presenting only significant FDR adjusted p value that is q < 0.05) to avoid making assumption about lower associations.

332

333

334

335

336


337

338

339

The NS1 sub-dimension and some C sub-dimensions (C1 and C4) were significantly and negatively associated with the PDQ-39 "Mobility" sub-score change.

PD patients were separated into the PDQ-39 total 340 "improvement" (n = 150) and the "no improvement" 341 (n = 153) groups according to the MCID [20]. Among 342 the "no improvement" group, 63% of patients had 343 a no clinically relevant amelioration (that is a delta 344 PDQ-39 total score between the MCID of -4.72 and 345 0) and 37% were not ameliorated (that is a delta 346 PDQ-39 total score superior to 0). Uncorrected sig-347 nificant differences of HA4, C and C3 scores were 348 found between the "improvement" group and the "no 349 improvement" group which did not maintain signifi-350 cance with FDR correction (Table 3).



Mann-Whitney tests: *q < 0.05 between the "paradoxically unimproved" and "paradoxically improved" or "realistic" groups

Fig. 2. Differences in Cooperativeness scores between groups of responding patients.

Differences between groups of responding patients (n = 264)

For this second exploratory objective, because of missing data in the MDS-UPDRS-IV, only 264/303 PD patients were used to form the three groups of responding patients according to their PDQ-39 and MDS-UPDRS-IV changes: 97 patients were in the "paradoxically unimproved" group, 149 in the "realistic" group, and 18 in the "paradoxically improved" group.

Reward Dependence scores were significantly higher in the "paradoxically improved" group compared to the "paradoxically unimproved" group (q=0.04 and CI=[1.0; 4.0]) (Fig. 1). Cooperativeness scores were significantly lower in the "paradoxically unimproved" group compared to the "realistic" and "paradoxically improved" groups (q = 0.03 andCI = [1.0; 3.0]; q = 0.04 and CI = [1.0; 5.0], respectively) (Fig. 2).

359

360

361

362

363

364

365

366

367

368

351

352

353

Concerning the HAMA, HAMD, LARS, and MoCA changes, there were no significant differences between groups.

372 DISCUSSION

399

400

401

402

In this study, presurgical TCI personality dimen-373 sions such as higher Cooperativeness and Novelty 374 Seeking sub-dimensions were associated with QoL 375 improvement after one year of DBS-STN in PD 376 population. This favorable outcome affected mainly 377 the physical component of QoL ("Mobility" evolu-378 tion). Secondly, patients with lower Cooperativeness 379 scores were more paradoxically unimproved after 380 DBS-STN: their objective motor complications 381 improvement was not translated into QoL improve-382 ment; while patients with higher Reward Dependence 383 scores were more paradoxically improved after DBS-384 STN: they had OoL improvement despite the absence 385 of motor complications reduction. 386

According to the literature [1-3, 22, 23], this 387 study reported an improvement in MDS-UPDRS and 388 PDQ-39 scores after one year of DBS-STN and a 389 significant reduction of dopaminergic treatments. A 390 slight amelioration of depression and anxiety was also 391 shown after DBS, whereas apathy and global cog-392 nition slightly deteriorated while remaining below 393 the threshold of apathy (LARS scale) and cogni-394 tive deficit (MoCA). Thus, DBS did not affect much 395 behavior of our PD patients which globally did not 396 develop either anxio-depressive state or apathy or 397 cognitive decline. 398

First, we confirm the results of our previous study showing that personality dimensions are associated with different QoL sub-scores before DBS-STN in PD [16].

Second, we found associations between personal-403 ity dimensions and QoL improvement after one year 404 of DBS-STN. Some Cooperativeness and Novelty 405 Seeking sub-dimensions (C1 (Social Acceptance), 406 C4 (Compassion), and NS1 (Exploratory Excitabil-407 ity)) were strongly related to the physical component 408 of QoL ("Mobility"): PD patients with high Coop-409 erativeness and Novelty Seeking before DBS-STN 410 had the best QoL improvement (physical component) 411 after DBS-STN. 412

Cooperativeness is a character reflecting social
maturity and described as a tendency to consider
and accept others [24, 25]. PD patients with higher
Cooperativeness probably better listen to their relatives and believe them, which can help them to

remember their past difficulties and to realize the strong motor improvement they benefit from DBS-STN. Indeed, it is usual that PD patients forget their past difficulties after DBS and need a reminder from their relatives or caregivers to become aware of their improvements [26]. In literature, low Cooperativeness was associated with treatment-resistance in depressive patients [27], and high Cooperativeness was also linked with good QoL or life satisfaction in different populations [28-30]. Also, this hypothesis makes sense because Cooperativeness mostly impact physical QoL improvement after DBS, only part of QoL that can be assessed by patients' relatives. Therefore, relatives probably have a more objective feeling on these improvements which may contrast with patients' subjective one. Moreover, it is interesting to compare personality-QoL associations before and after DBS. Before, Self-Directedness (representing the individual maturity) was associated with better QoL [16]; whereas, after, Cooperativeness (social maturity) becomes associated with better QoL. This may reflect that, before surgery, PD patients were used to their disease and to their relatives' comments because of adaptive process through chronic disease; whereas, after DBS, PD patients are confronted to abrupt changes [31] and motor improvement are often obvious. Thus, their relatives can appreciate these improvements and inform the patients, helping them to become more aware of these changes. Hence, before surgery, in case of a slowly evolving chronic disease, PD patients may rely more on their personal resources (individual maturity) to adapt and have a better QoL [16]; whereas, after DBS, they focus more on the external comments (social maturity) to adapt to the abrupt changes. It would thus be interesting to see the impact of Cooperativeness on QoL after longtime of DBS, when PD patients would have become used to these changes, with the PREDISTIM 5-year QoL evaluation.

Novelty Seeking is a temperament representing a tendency to respond positively and with excitation to new stimuli [24, 25]. It reflects good adaptability to new situations and motivation facing change. PD patients with higher Novelty Seeking may thus better adapt to the abrupt changes caused by DBS-STN and so really feel the strong motor improvement they benefit from the stimulation. In literature, higher Novelty Seeking was also associated with better global QoL and physical health in patients with schizophrenia [32].

Interestingly, Novelty Seeking and/or Cooperativeness are two personality dimensions potentially 467

468

469

418

419

420

421

422

423

121

425

522

523

524

525

526

527

528

529

implicated in placebo responses [33–35]. Therefore,
these two personality dimensions may enhance the
part of placebo effect induced by DBS-STN [36].
For example, the sub-dimension C3 (Helpfulness)
reflects solidarity and good level of team work which
may enhance placebo effect [37].

Moreover, our study has shown good associa-476 tions between the more objective evaluation of PD 477 symptoms (MDS-UPDRS) and the subjective eval-478 uation of PD QoL (PDQ-39). Mainly, the objective 479 motor examination, MDS-UPDRS-III, as well as the 480 motor complications assessed by the MDS-UPDRS-481 IV, were mostly associated with physical components 482 of the PDQ-39 evaluation, assuring that both scales 483 are reliable and evaluate PD patients in the same 484 way [38]. Nonetheless, some PD patients (43.6%) 485 had a feeling of evolution after DBS-STN that differs 486 from the objective motor complications examina-487 tion (MDS-UPDRS-IV). Indeed, eighteen patients 488 (6.8%) felt "paradoxically improved" after DBS: they 489 felt improvement of their QoL, whereas the MDS-490 UPDRS-IV showed no improvement of their motor 491 complications. Also, ninety-seven patients (36.7%) 492 felt "paradoxically unimproved" after DBS: they did 493 not feel any improvement of their OoL, whereas the 494 MDS-UPDRS-IV showed an improvement of their 495 motor complications. This dissociation between real-496 ity of PD symptoms improvement after DBS and PD 497 patients' feelings has already been shown in several 498 studies [5, 6] and can be explained by differences 499 between patients' expectations and reality, difficul-500 ties of psychosocial adjustment, mood and behavioral 501 changes [26, 31, 39, 40], etc. Moreover, we have 502 decided to focus our analysis on discrepancy between 503 QoL evolution and MDS-UPDRS-IV change since 504 DBS preferentially improves motor complications. 505

Here, paradoxically unimproved PD patients had 506 lower Cooperativeness scores than realistic and para-507 doxically improved ones. This result seems to be 508 congruent with our previous observation that lower 509 Cooperativeness scores before surgery lead to less 510 improvement of QoL after DBS-STN. Moreover, 511 paradoxically improved PD patients had higher 512 Reward Dependence scores than the paradoxically 513 unimproved ones. Reward Dependence temperament 514 is associated with sensitive, dependent and social 515 individuals [41]. It is a system facilitating condi-516 tioning to reward stimuli [25] and therefore may 517 be associated with placebo effect. Indeed, some 518 studies have found associations between higher 519 Reward Dependence scores and better outcomes 520 after interpersonal therapy [42] or antidepressants 521

[43]. Moreover, treatment adhesion was shown to be related to higher Reward Dependence temperament in a weight-loss therapy, probably thanks to better collaborative relationship with the clinicians [44]. Nonetheless, these differences between realistic, paradoxically improved or unimproved patients could not be explained by differences in cognitive or behavioral changes after DBS-STN.

This study has some limits. Being the first study on 530 this subject, only analyses of associations between 531 QoL outcomes and personality dimensions were 532 done. Thus, our results are not predictive but rather 533 suggestive. Hence, they should be used in order to 534 prevent disappointment of PD patients after DBS-535 STN (not to select PD patients for DBS) acting in two 536 ways: 1) by supporting them upstream and explain-537 ing them at best what they should expect of DBS, and 538 2) by preparing and encouraging their relatives to be 539 really present with the patients after the operation to 540 enhance their cooperation (which seems to facilitate 541 their positive outcomes). Additionally, our models 542 explaining less than ten percent of the variance (R^2) 543 of QoL improvement after DBS-STN, we are aware 544 that personality dimensions are not enough to guar-545 anty PD patients' OoL improvement after stimulation 546 and that other variable are needed to explain at best 547 QoL outcome after surgery. However, our focus being 548 concentrated on personality dimensions' evaluation, 549 we did not look for other potential predictive variables 550 as it will be the aim of the main PREDI-STIM study. 551 Finally, only personality dimensions before DBS 552 were evaluated (there was no re-evaluation of person-553 ality after stimulation), and it remains possible that 554 some personality dimensions evolve after DBS. Even 555 if temperaments are not supposed to change with 556 time [9], personality in PD patients seems to evolve 557 with the disease course particularly with the intro-558 duction of dopaminergic treatments [45]. DBS could 559 also impact personality as shown by some studies 560 [46-50]. In any case, our aim was to find "predic-561 tive" factors of QoL improvement after DBS. Thus, 562 even if personality changes after stimulation, it is not 563 supposed to affect our results. Lastly, our three groups 564 of responding PD patients ("paradoxically unim-565 proved", "realistic" and "paradoxically improved") 566 were done according to their motor complications 567 improvement (reflected by MDS-UPDRS part-IV) 568 since it is the main purpose of DBS-STN action. 569 Nonetheless, improvements of non-motor symptoms 570 (pain, fatigue etc.) were not accounted in these anal-571 yses, although non-motor symptoms can benefit of 572 DBS-STN [51] and are best predictors of QoL in PD 573

[52], because we were interested in more objective 574 assessments than MDS-UPDRS parts I and II. More-575 over, we are aware that using MCIDs to classify into 576 groups of "improvement" or "no improvement" may 577 not precisely reflect the evolution of patients after 578 DBS, mainly since at this stage of motor fluctua-579 tions a change of 0.9 points in the MDS-UPDRS 580 part-IV may not be sufficient to be clinically sig-581 nificant. Nonetheless, the choice of this MCID was 582 done accordingly with literature. Ultimately, we are 583 aware that there are other models of personality that 584 could have been explore in this study to depict a more 585 complete exploration of personality associated with 586 QoL. Nonetheless, the TCI being a long question-587 naire, we thought that using a multilayer approach 588 (through different personality investigations) would 589 have been too complex in clinical practice and too 590 tiring for the PD patients. 591

In conclusion, PD patients with higher Coopera-592 tiveness and Novelty Seeking scores at baseline seem 593 to have the best QoL outcome after one year of DBS-594 STN in the physical component of QoL. A tendency 595 of being more trustful towards relatives and more 596 motivated by changes could explained the ability 597 of these PD patients to feel a better OoL improve-598 ment following the abrupt changes after surgery. 599 Moreover, PD patients with low Cooperativeness 600 were more paradoxically unimproved after DBS, 601 whereas PD patients with high Reward Dependence 602 were more paradoxically improved after DBS. There-603 fore, systematic TCI examination could be proposed 604 as standard evaluation before DBS. Subsequently, 605 according to PD patients' scores at the Novelty 606 Seeking and Cooperativeness dimensions, specific 607 educational programs should be proposed to patients 608 with higher risk of QoL unimprovement after DBS to 609 prepare them at best for the stimulation. For this, we 610 are now looking for cut-off scores for these dimen-611 sions. 612

613 ACKNOWLEDGMENTS

The study was funded by the France Parkinson charity and French Ministry of Health (PHRC national 2012). This is an ancillary study to Protocol ID: 2013-A00193-42; ClinicalTrials.gov: NCT02360683.

We thank all participants for their cooperation, and Déborah Meligne from ToNIC (Toulouse NeuroImaging Center–INSERM, University of Toulouse III) for her reflection. The authors are also grateful for support from the French clinical research network NS-Park/F-Crin and the Fédération de la Recherche Clinique du CHU de Lille (with Anne-Sophie Rolland, Alain Duhamel, Maeva Kheng, Julien Labreuch, Dominique Deplanque, Edouard Millois, Nolwen Dautrevaux, Victor Laugeais, Maxime Caillier, Aymen Aouni, Pauline Guyon, Francine Niset, Valérie Santraine, Marie Pleuvret, Julie Moutarde and Laetitia Thibault).

623

624

625

626

627

628

620

630

631

We also thank all the members of the PREDI-STIM 632 study group: Dr Caroline Moreau, Pr Luc Defebvre, 633 Dr Nicolas Carriere, Dr Guillaume Grolez, Dr Guil-634 laume Baille, Dr Kreisler, Pr Jean-Pierre Pruvo, Pr 635 Leclerc, Dr Renaud Lopes, Dr Romain Viard, Dr 636 Gregory Kuchcinski, Mr Julien Dumont, Pr Kathy 637 Dujardin, Mme M Delliaux, Mrs M Brion, Dr Gus-638 tavo Touzet, Pr Nicolas Reyns, Pr Arnaud Delval, 639 Mrs Valerie Santraine, Mrs Marie Pleuvret, Mrs 640 Nolwen Dautrevaux, Mr Victor Laugeais, Thavarak 641 Ouk, Camille Potey, Celine Leclercq and Elise 642 Gers (for Lille University Hospital); Jean-Christophe 643 Corvol, Marie-Vidailhet, Elodie Hainque, Marie-644 Laure Welter, Lucette Lacomblez, David Grabli, 645 Emmanuel Roze, Yulia Worbe, Cécile Delorme, Hana 646 You, Jonas Ihle, Raquel Guimeraes-Costa, Florence 647 Cormier-Dequaire, Aurélie Méneret, Andréas Hart-648 mann, Louise-Laure Mariani, Stéphane Lehericy, 649 Virginie Czernecki, Fanny Pineau, Frédérique Bozon, 650 Camille Huiban, Eve Benchetrit, Carine Karachi, 651 Soledad Navarro, Philippe Cornu, Arlette Welaratne, 652 Carole Dongmo-Kenfack, Lise Mantisi, Nathalie 653 Jarry, Sophie Aix and Carine Lefort (for the AP-654 HP, Paris); Dr Tiphaine Rouaud, Pr Philippe Damier, 655 Pr Pascal Derkinderen, Dr Anne-Gaelle Corbille, Dr 656 Elisabeth Calvier-Auffray, Mrs Laetitia Rocher, Mrs 657 Anne-Laure Deruet, Dr Raoul Sylvie, Dr Roualdes 658 Vincent and Mrs Le Dily Séverine (for Nantes 659 University Hospital); Dr Ana Marques, Dr Beran-660 gere Debilly, Pr Franck Durif, Dr Philippe Derost, 661 Dr Charlotte Beal, Carine Chassain, Laure Delaby, 662 Tiphaine Vidal, Pr Jean Jacques Lemaire, Isabelle 663 Rieu and Elodie Durand (for Clermont-Ferrand 664 University Hospital); Pr Alexandre Eusebio, Pr Jean-665 Philippe Azulay, Dr Tatiana Witjas, Dr Frédérique 666 Fluchère, Dr Stephan Grimaldi, Pr Nadine Girard, 667 Eve Benchetrit, Marie Delfini, Dr Romain Carron, Pr 668 Jean Regis, Dr Giorgio Spatola and Camille Mag-669 naudet (for the AP-HM, Marseille); Dr Ansquer 670 Solène, Dr Benatru Isabelle, Dr Colin Olivier, Pr 671 Houeto JL, Pr Guillevin Remy, Mrs Fradet Anne, Mrs 672 Anziza Manssouri, Mrs Blondeau Sophie, Dr Richard 673 Philippe, Dr Cam Philippe, Dr Page Philippe, Pr 674

Bataille Benoit, Mrs Rabois Emilie and Mrs Guille-675 main Annie (for Poitiers University Hospital); Dr 676 Drapier Sophie, Dr Frédérique Leh, Dr Alexandre 677 Bonnet, Pr Marc Vérin, Dr Jean-Christophe Ferré, 678 Mr Jean François Houvenaghel, Pr Claire Haege-679 len, Mrs Francoise Kestens and Mrs Solenn Ory 680 (for Rennes University Hospital); Pr Pierre Burbaud, 681 Dr Nathalie Damon-Perriere, Pr Wassilios Meiss-682 ner, Pr Francois Tison, Dr Stéphanie Bannier, Dr 683 Elsa Krim, Pr Dominique Guehl, Sandrine Molinier-684 Blossier, Morgan Ollivier, Marion Lacoste, Nicolas 685 Auzou, Marie Bonnet, Pr Emmanuel Cuny, Dr Julien 686 Engelhardt, Olivier Branchard, Clotilde Huet and 687 Julie Blanchard (for Bordeaux University Hospital): 688 Pr Rascol Olivier, Dr Christine Brefel Courbon, Dr 689 Fabienne Orv Magne, Dr Marion Simonetta Moreau, 690 Pr Christophe Arbus, Pr Fabrice Bonneville, Dr Jean 691 Albert Lotterie, Marion Sarrail, Charlotte Scotto 692 d'Apollonia, Pr Patrick Chaynes, Pr François Caire 693 and Estelle Harroch (for Toulouse University Hos-694 pital); Pr David Maltete, Dr Romain Lefaucheur, 695 Dr Damien Fetter, Dr Nicolas Magne, Mrs San-696 drine Bioux, Mrs Maud Loubeyre, Mrs Evangéline 697 Bliaux, Mrs Dorothée Pouliguen, Pr Stéphane Der-698 rey, Mrs Linda Vernon and Dr Frédéric Ziegler 699 (for Rouen University Hospital); Mathieu Anheim, 700 Ouhaid Lagha-Boukbiza, Christine Tranchant, Odile 701 Gebus, Solveig Montaut, S Kremer, Nadine Lon-702 gato, Clélie Phillips, Jimmy Voirin, Marie des Neiges 703 Santin, Dominique Chaussemy and Dr Amaury 704 Mengin (for Strasbourg University Hospital); Dr Car-705 oline Giordana, Dr Claire Marsé, Lydiane Mondot, 706 Bruno Giordana, Robin Kardous, Bernadette Bailet, 707 Héloise Joly, Denys Fontaine, Dr Aurélie Leplus, 708 Amélie Faustini and Vanessa Ferrier (for Nice Uni-709 versity Hospital); Pr Pierre Krystkowiak, Dr Mélissa 710 Tir, Pr Jean-Marc Constans, Sandrine Wannepain, 711 Audrey Seling, Dr Michel Lefranc, Stéphanie Blin 712 and Béatrice Schuler (for Amiens University Hos-713 pital); Pr Stephane Thobois, Dr Teodor Danaila, Dr 714 Chloe Laurencin, Pr Yves Berthezene, Dr Roxana 715 Ameli, Helene Klinger, Dr Gustavo Polo, Patrick 716 Mertens, A Nunes and Elise Metereau (for Lyon 717 University Hospital); Dr Lucie Hopes, Dr Solène 718 Frismand, Dr Emmanuelle Schmitt, Mrs Mylène 719 Meyer, Mrs Céline Dillier, Pr Sophie Colnat and 720 Mrs Anne Chatelain (for Nancy University Hospi-721 tal); Dr Jean- Philippe Brandel, Dr Cécile Hubsch, 722 Dr Patte Karsenti, Dr Marie Lebouteux, Dr Marc 723 Ziegler, Dr Christine Delmaire, Dr Julien Savatowky, 724 Mrs Juliette Vrillac, Mrs Claire Nakache, Dr Vin-725 cent D'Hardemare and Mr Lhaouas Belamri (for the 726

Rotschild fondation of Paris); Dr Philippe Graveleau, 727 Dr Camille Decrocq, Dr Frédéric Bourdain, Dr Vadim 728 Afanassiev, Dr Anne Boulin, Mrs Elodie Dupuy, Dr 729 Bérénice Gardel, Pr Béchir Jarraya, Mrs Delphine 730 Lopez and Mr Christophe Fruit (for the Foch Hos-731 pital of Paris-Saclay University); David Gay, Robin 732 Bonicel, Fouzia El Mountassir, Clara Fischer, Jean-733 Francois Mangin, Marie Chupin and Yann Cointepas 734 (for CATI (MRI acquisition management, prepro-735 cessing and data management)); Bertrand Accart, 736 Patrick Gelé, Florine Fievet, Matthieu Chabel, Vir-737 ginie Derenaucourt, Loïc Facon, Yanick Tchantchou 738 Njosse and Dominique Deplanque (for CRB of 739 Lille (Center of Biological Resources)); and Alain 740 Duhamel, Lynda Djemmane and Florence Duflot (for 741 Data management of Lille). 742

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

REFERENCES

- Benabid AL, Chabardes S, Mitrofanis J, Pollak P (2009) Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. *Lancet Neurol* 8, 67-81.
- [2] Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G (2006) Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. *Mov Disord* 21 Suppl 14, S290-304.
- [3] Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349, 1925-1934.
- [4] Castelli L, Perozzo P, Zibetti M, Crivelli B, Morabito U, Lanotte M, Cossa F, Bergamasco B, Lopiano L (2006) Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. *Eur Neurol* 55, 136-144.
- [5] Albanese A, Piacentini S, Romito LM, Leone M, Franzini A, Broggi G, Bussone G (2005) Suicide after successful deep brain stimulation for movement disorders. *Neurology* 65, 499-500.
- [6] Agid Y, Schüpbach M, Gargiulo M, Mallet L, Houeto JL, Behar C, Maltête D, Mesnage V, Welter ML (2006) Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so? In *Parkinson's Disease and Related Disorders*, Riederer P, Reichmann H, Youdim MBH, Gerlach M, eds. Springer, Vienna, pp. 409-414.
- [7] Cella DF (1994) Quality of life: Concepts and definition. J Pain Symptom Manage 9, 186-192.
- [8] Lucas-Carrasco R, Den Oudsten BL, Eser E, Power MJ (2014) Using the Satisfaction with Life Scale in people with Parkinson's disease: A validation study in different European countries. *ScientificWorldJournal* 2014, 680659.
- [9] Hansenne M (2001) Le modèle biosocial de la personnalité de Cloninger. Annee Psychol 101, 155-181.

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

- [10] Cloninger C, Svrakic D, Przybeck T (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50, 975-990.
- [11] Santangelo G, Garramone F, Baiano C, D'Iorio A, Piscopo F, Raimo S, Vitale C (2018) Personality and Parkinson's disease: A meta-analysis. *Parkinsonism Relat Disord* 49, 67-74.
- [12] Miettunen J, Kantojärvi L, Veijola J, Järvelin M, Joukamaa M (2006) International comparison of Cloninger's temperament dimensions. *Pers Individ Dif* 41, 1515-1526.
- [13] Miettunen J, Lauronen E, Kantojarvi L, Veijola J, Joukamaa M (2008) Inter-correlations between Cloninger's temperament dimensions–a meta-analysis. *Psychiatry Res* 160, 106-114.
- [14] Fassino S, Amianto F, Levi M, Rovera GG (2003) Combining the Rorschach test and the Temperament Character Inventory: a new perspective on personality assessment. *Psychopathology* **36**, 84-91.
- [15] Pélissolo A, Lépine J-P (1997) Traduction française et premières études de validation du questionnaire de personnalité TCI. [Validation study of the French version of the TCI.]. Ann Med Psychol (Paris) 155, 497-508.
- [16] Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, 803 804 Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque 805 806 E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, 807 Marques A-R, Danaila T, Eusebio A, Devos D, Brefel-Courbon C, PREDI-STIM study group (2020) Personality 808 dimensions are associated with quality of life in fluctuating 809 Parkinson's disease patients (PSYCHO-STIM). J Parkin-810 sons Dis 10, 1057-1066. 811
- 812 [17] Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio 813 C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, 814 Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, 815 Schrag A, Teresi JA, Hilten JJV, LaPelle N (2007) Move-816 ment Disorder Society-sponsored revision of the Unified 817 Parkinson's Disease Rating Scale (MDS-UPDRS): Process, 818 819 format, and clinimetric testing plan. Mov Disord 22, 41-47.
- [18] Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke
 CE (2010) Systematic review of levodopa dose equivalency
 reporting in Parkinson's disease. *Mov Disord* 25, 2649 2653.
- Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The
 development and validation of a short measure of function ing and well being for individuals with Parkinson's disease.
 Qual Life Res 4, 241-248.
- [20] Horváth K, Aschermann Z, Kovács M, Makkos A, Harmat M, Janszky J, Komoly S, Karádi K, Kovács N (2017)
 Changes in quality of life in Parkinson's disease: how large must they be to be relevant? *Neuroepidemiology* 48, 1-8.
- [21] Makkos A, Kovács M, Pintér D, Janszky J, Kovács N (2019)
 Minimal clinically important difference for the historic parts
 of the Unified Dyskinesia Rating Scale. *Parkinsonism Relat Disord* 58, 79-82.
- [22] Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack 836 837 P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, 838 Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider G-H, 839 Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel 840 Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto J-L, 841 842 Bataille B, Maltête D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage 843 F, Régis J-M, Witjas T, Thobois S, Mertens P, Kloss M, 844 Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, 845

Schade-Brittinger C, Deuschl G (2013) Neurostimulation for Parkinson's disease with early motor complications. *N Engl J Med* **368**, 610-622.

- [23] Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid A (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Mede 339, 1105-1111.
- [24] Morlon EM (2012) Le modele psychobiologique de Cloninger pour evaluer la personnalite du patient douloureux: etude en medecine generale (Thesis). Universite de Limoges.
- [25] Pelissolo PA (2015) Le modèle de personnalité de Cloninger et le questionnaire TCI. 74.
- [26] Thomson CJ, Segrave RA, Racine E, Warren N, Thyagarajan D, Carter A (2020) "He's back so i'm not alone": the impact of deep brain stimulation on personality, self, and relationships in Parkinson's disease. *Qual Health Res* 30, 2217-2233.
- [27] Takahashi M, Shirayama Y, Muneoka K, Suzuki M, Sato K, Hashimoto K (2013) Personality traits as risk factors for treatment-resistant depression. *PLoS One* 8, e63756.
- [28] Demirci K, Demirci S, Taşkıran E, Kutluhan S (2017) The effects of temperament and character traits on perceived social support and quality of life in patients with epilepsy. *Epilepsy Behav* 74, 22-26.
- [29] Park H, Suh BS, Kim WS, Lee H-K, Park S-C, Lee K (2015) Character profiles and life satisfaction. *Compr Psychiatry* 58, 172-177.
- [30] Masthoff ED, Trompenaars FJ, Van Heck GL, Hodiamont PP, De Vries J (2007) The relationship between dimensional personality models and quality of life in psychiatric outpatients. *Psychiatry Res* 149, 81-88.
- [31] Schüpbach WM, Agid Y (2008) Psychosocial adjustment after deep brain stimulation in Parkinson's disease. *Nat Clin Pract Neurol* 4, 58-59.
- [32] Ritsner M, Farkas H, Gibel A (2003) Satisfaction with quality of life varies with temperament types of patients with schizophrenia. *J Nerv Ment Dis* **191**, 668-674.
- [33] Geers AL, Weiland PE, Kosbab K, Landry SJ, Helfer SG (2005) Goal activation, expectations, and the placebo effect. *J Person Soc Psychol* 89, 143-159.
- [34] Schweinhardt P, Seminowicz DA, Jaeger E, Duncan GH, Bushnell MC (2009) The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response. *J Neurosci* 29, 4882-4887.
- [35] Jakšić N, Aukst-Margetić B, Jakovljević M (2013) Does personality play a relevant role in the placebo effect? *Psychiatr Danub* 25, 17-23.
- [36] de la Fuente-Fernández R (2004) Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson's disease. *Parkinsonism Relat Disord* **10**, 125-127.
- [37] Blasini M, Peiris N, Wright T, Colloca L (2018) The role of patient–practitioner relationships in placebo and nocebo phenomena. *Int Rev Neurobiol* **139**, 211-231.
- [38] Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, Álvarez-Sánchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martínez-Castrillo JC, Mendoza-Rodríguez A, Moore HP, Rodríguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2014) Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. *Eur J Neurol* 21, 519-524.
- [39] Bell E, Maxwell B, McAndrews MP, Sadikot AF, Racine E (2011) A review of social and relational aspects of deep brain stimulation in Parkinson's disease informed

910

781

782 783

784

785

786

787

788

789

790

791

792

793

794 795

796

797

798

799

800

801

802

by healthcare provider experiences. *Parkinsons Dis* 2011, 871874.

911

912

944

- [40] Lewis CJ, Maier F, Horstkötter N, Zywczok A, Witt K,
 Eggers C, Meyer TD, Dembek TA, Maarouf M, Moro E,
 Zurowski M, Woopen C, Kuhn J, Timmermann L (2015)
 Subjectively perceived personality and mood changes
 associated with subthalamic stimulation in patients with
 Parkinson's disease. *Psychol Med* 45, 73-85.
- 919
 [41]
 Cloninger CR, Przybeck TR, Svrakic DM, Wetzel RD

 920
 (1994) The temperament and character inventory (TCI): a

 921
 guide to its development and use, Center for Psychobiology

 922
 of Personality, Washington University, St. Louis, MO.
- [42] Joyce PR, McKenzie JM, Carter JD, Rae AM, Luty SE,
 Frampton CMA, Mulder RT (2007) Temperament, character
 and personality disorders as predictors of response to inter personal psychotherapy and cognitive-behavioural therapy
 for depression. Br J Psychiatry 190, 503-508.
- [43] Tome MB, Cloninger CR, Watson JP, Isaac MT (1997)
 Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. *J Affect Disord* 44, 101-109.
- [44] De Panfilis C, Torre M, Cero S, Salvatore P, Dall'Aglio E, Marchesi C, Cabrino C, Aprile S, Maggini C (2008) Personality and attrition from behavioral weight-loss treatment for obesity. *Gen Hosp Psychiatry* **30**, 515-520.
- Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, 936 [45] 937 Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland A-S, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana 938 B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou 939 N, Belamri L, Tir M, Marques A-R, Thobois S, Eusebio 940 A, Corvol JC, Devos D, Brefel-Courbon C, PREDI-STIM 941 942 study group (2021) Personality dimensions of patients can 943 change during the course of parkinson's disease. PLoS One

16, e0245142.

- [46] Lhommée E, Boyer F, Wack M, Pélissier P, Klinger H, Schmitt E, Bichon A, Fraix V, Chabardès S, Mertens P, Castrioto A, Kistner A, Broussolle E, Thobois S, Krack P (2017) Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation. *Mov Disord* **32**, 1191-1200.
- [47] Pham U, Solbakk A-K, Skogseid I-M, Toft M, Pripp AH, Konglund AE, Andersson S, Haraldsen IR, Aarsland D, Dietrichs E, Malt UF (2015) Personality changes after deep brain stimulation in Parkinson's disease. *Parkinsons Dis* 2015, 490507.
- [48] Fassino S, Abbate Daga G, Gramaglia C, Pierò A, Zibetti M, Castelli L, Cinquepalmi A, La Notte M, Lopiano L (2010) Novelty-seeking in Parkinson's disease after deep brain stimulation of the subthalamic nucleus: a case-control study. *Psychosomatics* **51**, 62-67.
- [49] Dupouy J (2014) Personnalité et maladie de Parkinson idiopathique: à propos d'une revue de la littérature et de deux études expérimentales (Thesis). Université Toulouse.
- [50] Abbate-Daga G, Marzola E, Amianto F, Zibetti M, Merola A, Lanotte M, Lopiano L, Fassino S (2014) Personality and deep brain stimulation of the subthalamic nucleus in Parkinson's disease. *Int Neuropsychiatr Dis J* 2, 356-367.
- [51] Kurtis MM, Rajah T, Delgado LF, Dafsari HS (2017) The effect of deep brain stimulation on the non-motor symptoms of Parkinson's disease: a critical review of the current evidence. *NPJ Parkinsons Dis* **3**, 16024.
- [52] Skorvanek M, Rosenberger J, Minar M, Grofik M, Han V, Groothoff JW, Valkovic P, Gdovinova Z, van Dijk JP (2015) Relationship between the non-motor items of the MDS–UPDRS and Quality of Life in patients with Parkinson's disease. *J Neurol Sci* 353, 87-91.

968

969

970

971

972

973

974

975